GEN Exclusives

More »

GEN News Highlights

More »
Jul 17, 2008

Cellumen Creates New Firm from Its Personalized Medicine Unit

  • Cellumen has spun off its personalized medicine unit, which will be called Cernostics Pathology. The new entity will provide tissue-based diagnostic products and services as well as digital imaging pathology.

    Cernostics Pathology will build upon Cellumen’s current collaborations. The first diagnostic/theranostic test being developed is for breast cancer as part of an alliance with the Mayo Clinic and Foundation.

    "Cellumen’s successful application of cellular systems biology to drug discovery, drug development, and personalized medicine over the last three years has yielded strong interest across each of these application areas,” comments D. Lansing Taylor, Ph.D., CEO of Cellumen. “Cellumen will maintain its core business by focusing on the interface between early drug discovery and early toxicity testing.”

    Cernostics Pathology will also create a complete digital imaging pathology platform and build advanced informatics tools to manage, mine, and classify patient tissue samples.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »